Basmah Jalil, MD
Rheumatology · Tulsa, OKNPI 1649587635
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,635 of the $9,723 with a category attached, or 68.2%. It is spread thinly across 30 manufacturers, the largest accounting for just 21.7%. Reporting peaked in 2024 at $3,513 and has fallen 64.7% since, to $1,239 in 2025.
Across 363 payments — averaging $26.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$2K
- AbbVie$2K
- Modernatx, Inc.$1K
- Janssen Research & Development, LLC$897
- Amgen$705
- UCB, Inc.$703
- plus $2K from 24 others
Across 626 payments — averaging $8282.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$4.7M
- Seqirus USA Inc$368K
- AstraZeneca$59K
- Janssen Research & Development, LLC$23K
- Orasure Technologies Inc.$6K
What the payments were for
- Travel & lodging$3,08832%
- Food & beverage$6,63568%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 16 | $2,115 |
| AbbVie | 118 | $1,529 |
| Modernatx, Inc. | 12 | $1,433 |
| Janssen Research & Development, LLC | 8 | $897 |
| Amgen(2 entities) | 40 | $705 |
| UCB, Inc. | 36 | $703 |
| Lilly USA, LLC | 18 | $327 |
| Johnson & Johnson | 18 | $312 |
| GSK | 12 | $268 |
| Novartis | 18 | $219 |
| AstraZeneca(2 entities) | 6 | $204 |
| Mallinckrodt Hospital Products Inc. | 9 | $174 |
| E.r. Squibb & Sons, L.L.C. | 9 | $130 |
| Pfizer | 10 | $129 |
| Sobi, Inc | 4 | $102 |
| Aurinia Pharma U.S., Inc. | 5 | $81 |
| Actelion Pharmaceuticals US, Inc. | 2 | $56 |
| Boehringer Ingelheim | 3 | $56 |
| Collegium Pharmaceutical, Inc. | 3 | $49 |
| Antares Pharma, Inc. | 3 | $40 |
| Madrigal Pharmaceuticals | 1 | $29 |
| Genentech USA, Inc. | 2 | $27 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Mallinckrodt Enterprises LLC | 2 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Radius Health, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $11 |
| Almatica Pharma LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bimzelx$125
How this compares
$9,723 in reported general payments places this provider in the 65th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xeljanz XrTofacitinib Citrate | 32 | $174,021 |
| RinvoqUpadacitinib | 27 | $169,808 |
| Actemra ActpenTocilizumab | 29 | $104,764 |
| Taltz AutoinjectorIxekizumab | 13 | $85,918 |
| Humira PenAdalimumab | 12 | $81,739 |
| Orencia ClickjectAbatacept | 14 | $78,517 |
| OtezlaApremilast | 15 | $71,031 |
| OrenciaAbatacept | 14 | $70,115 |
| XeljanzTofacitinib Citrate | 12 | $67,718 |
| BenlystaBelimumab | 14 | $61,398 |
| ActemraTocilizumab | 12 | $28,314 |
| Leflunomide | 105 | $5,981 |
| Hydroxychloroquine Sulfate | 124 | $5,300 |
| Cevimeline Hcl | 19 | $4,924 |
| MethotrexateMethotrexate Sodium | 91 | $3,093 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $1,529 | $169,80827 claims |
| AmgenOtezla | $705 | $71,03115 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $130 | $70,11514 claims |
| PfizerXeljanz | $129 | $67,71812 claims |
| GSKBenlysta | $268 | $61,39814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 67 rheumatology providers in Oklahoma.
Other rheumatology in Tulsa
- Debbie FoleyTulsa$281K
- Mary Hinojos MamutTulsa$21K
- Manuel CalvinTulsa$19K
- Alan MartinTulsa$18K
- William SurbeckTulsa$17K
- Michael MalloyTulsa$13K
- Ellen ZanetakisTulsa$10K
- Priyatha GarlapatiTulsa$8K
- James McKayTulsa$5K
- Lindsay CunninghamTulsa$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.